HOME > English Home > Research & Development > R&D Pipeline

R&D Pipeline (In-House)

As of November 2014
Development
Stage
Product name /
Generic name /
Development Code
Development
Classification
Therapeutic
Target
Approved Salagen® /
Pilocarpine
Kissei Dry mouth
- Additional dosage form: Granule form -
NDA Dopram® /
Doxapram
Kissei (Application with Public Knowledge) An apneic attack of prematurity
- Additional indication -
NDA Urief® /
Silodosin
Kissei / Co-development with Daiichi Sankyo (Japan) Dysuria associated with benign prostatic hyperplasia
- Alpha 1A antagonist -
- Additional dosage form: oral disintegration tablet -
NDA preparation PA21 In-licensed /
Vifor-Fresenius Medical Care Renal Pharma (Switzerland)
Hyperphosphatemia in hemodialysis patients
- Phosphate binder -
Phase III KPS-0373 In-licensed / Shionogi(Japan) Spinocerebellar ataxia
- Product mimetic of TRH action -
Phase II Ozagrel /
KCT-0809
Kissei / Co-development with Teika (Japan) Dry-eye
- Restoration of corneal and conjunctival epithelium -
Phase II KLH-2109 Kissei Endometriosis / uterine fibroids
- GnRH antagonist -
Phase II KWA-0711 Kissei Chronic constipation
- Inhibitor of water absorption in the gastrointestinal tract -
Phase II KUX-1151 Kissei Gout and hyperuricemia
- Decrease formation of uric acid -
- Uricosuric effect -
Phase I / II YS110 In-licensed / Y's AC, University of Tokyo, JST (Japan) Malignant mesothelioma
- Humanized anti-CD26 monoclonal antibody -

R&D Pipeline (Out-Licensing)

As of November 2014
Development Stage Generic Name / Development Code Development
Company
Territory Therapeutic Target
NDA Mitiglinide Eisai
(Japan)
ASEAN ※1 Type 2 diabetes mellitus
NDA Silodosin Eisai
(Japan)
ASEAN, India, SriLanka ※2 Dysuria associated with benign prostatic hyperplasia
Phase II Bedoradrine MediciNova
(U.S.)
Worldwide, except for Japan Acute exacerbation of asthma /
Preterm labor
Phase I Bedoradrine MediciNova
(U.S.)
Worldwide, except for Japan COPD
Phase I KUX-1151 Pfizer
(U.S.)
Worldwide, except for Japan Gout and Hyperuricemia

※1: Launched in Thailand, Philippines, Approved in Myanmar and NDA in 3 countries
※2: Launched in Thailand, Approved in India, NDA in 7 ASEAN countries

© 2012- Kissei Pharmaceutical Co., Ltd. All rights reserved.